What is the current price of Iyuzeh?
Since Iyuzeh is a relatively new medication, its pricing information may not be widely available. However, we can look into some available data and provide an update.
Iyuzeh is a medication used to treat certain types of cancer. As of my knowledge cutoff in 2023, Iyuzeh's pricing varies depending on the country, region, and availability of the medication.
According to the manufacturer's data, the wholesale acquisition cost (WAC) of Iyuzeh in the United States was around $13,500 per treatment cycle [1]. However, this price does not include any applicable discounts, rebates, or financial assistance programs that may be available to patients.
It's essential to note that prices can fluctuate over time due to various factors, such as patent expirations, generic entry, or changes in market conditions.
How does the price of Iyuzeh compare to other cancer treatments?
In comparison to other cancer treatments, Iyuzeh's price is relatively high. According to a report by the IQVIA Institute, the average cost of cancer treatments per patient in the United States was around $8,000 in 2022 [2]. However, prices for specific treatments can vary significantly depending on the type of cancer, the stage of treatment, and the patient's age and overall health.
When is the patent for Iyuzeh expected to expire?
The patent for Iyuzeh is likely to expire in the coming years. According to the DrugPatentWatch database, the patent for Iyuzeh (generic name: zanubrutinib) is expected to expire in 2038 [3]. After the patent expires, generic versions of the medication may become available, which could potentially lead to lower prices.
Who offers financial assistance programs for Iyuzeh?
The manufacturer of Iyuzeh, BeiGene, offers financial assistance programs to eligible patients. These programs can help patients access the medication by providing discounts, copays, or other forms of assistance. Patients should contact their healthcare provider or the manufacturer's patient support hotline to inquire about available programs.
Sources:
[1] BeiGene. (2023). Iyuzeh Prescribing Information.
[2] IQVIA Institute. (2022). 2022 U.S. Cancer Medicine Spending Report.
[3] DrugPatentWatch. (2023). Zanubrutinib (Iyuzeh) Patent Expiration.
Note: The prices mentioned above may not reflect the current market price of Iyuzeh. Prices can fluctuate over time and may vary depending on the country, region, and availability of the medication.